Please Note: This trial is no longer enrolling new participants
A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)
| Protocol No. | CTO-21-159 | Scope | National |
|---|---|---|---|
| Principal Investigator | Kathy Miller | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase II |
